Arthritis

Upadacitinib Demonstrates Safety and Efficacy for Atopic Dermatitis

July 21, 2020

Article

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

Meloxicam Better than Placebo, CBT for Knee Osteoarthritis

July 20, 2020

Article

Despite negative trial resutls, the data support the posibility of tapering off NSAIDs and the plausibility of self-management approaches like CBT.

ACR Supports Use of Telemedicine for Rheumatology

July 01, 2020

Article

The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.

Richard Furie, MD: The Difficulty in Finding Lupus Treatments

June 16, 2020

Article

Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.

Filgotinib Effective for Patients With Rheumatoid Arthritis

June 09, 2020

Article

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Tocilizumab Shows Similar Efficacy to Other Targeted Immune Modulators

June 09, 2020

Article

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

Philip Mease, MD: The Relationship Between Psoriatic Arthritis and IBD

June 07, 2020

Article

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Tofacitinib Reduces Psychiatric Disorder Rates in Rheumatoid Arthritis Patients

June 07, 2020

Article

Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.

Serious Infection More Likely in Older Rheumatoid Arthritis Patients

June 07, 2020

Article

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

Upadacitinib Improves Rheumatoid Arthritis Symptoms Over Abatacept

June 06, 2020

Article

The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.

x